| 12.77 -0.73 (-5.41%) | 07-14 09:53 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 18.16 | 1-year : | 21.21 |
| Resists | First : | 15.55 | Second : | 18.16 |
| Pivot price | 13.72  |
|||
| Supports | First : | 12.27 | Second : | 10.25 |
| MAs | MA(5) : | 14.31 |
MA(20) : | 13.19 |
| MA(100) : | 12.26 |
MA(250) : | 17.4 |
|
| MACD | MACD : | 0.6 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 64.6 |
D(3) : | 73.8 |
| RSI | RSI(14): 53 |
|||
| 52-week | High : | 55.88 | Low : | 5.2 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ KRRO ] has closed above bottom band by 41.6%. Bollinger Bands are 23.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 14.48 - 14.55 | 14.55 - 14.61 |
| Low: | 12.94 - 13.02 | 13.02 - 13.07 |
| Close: | 13.39 - 13.51 | 13.51 - 13.6 |
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
Fri, 10 Jul 2026
Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Wed, 08 Jul 2026
Price to earnings forward of Korro Bio, Inc. – NASDAQ:KRRO - TradingView
Wed, 08 Jul 2026
Korro Bio, Inc. (KRRO) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Tue, 07 Jul 2026
Korro Bio director Formela sells $1.54m in shares - Investing.com
Tue, 07 Jul 2026
Form 4 Korro Bio Inc For: 7 July By Investing.com - Investing.com Canada
Mon, 29 Jun 2026
Korro Bio, Inc.(NasdaqCM: KRRO) added to Russell Microcap Growth Benchmark Index - marketscreener.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 9.37e+006 (%) |
| Held by Institutions | 0.9 (%) |
| Shares Short | 1,270 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.932e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 154 % |
| Return on Equity (ttm) | -26.9 % |
| Qtrly Rev. Growth | 3.84e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -41.61 |
| EBITDA (p.s.) | -2.10095e+007 |
| Qtrly Earnings Growth | -11.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -70 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.33 |
| Price to Cash Flow | 3.43 |
| Dividend | 0 |
| Forward Dividend | 1.71e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|